ramadan_mahmoud814

Ramadan Aboelhassan Ahmed Mahmoud (Ramadan A mahmoud)

Lecturer - Lecture of Pediatrics

Faculty of medicine

Address: pediatrics departmet, sohag Faculty Of medicine, Egypt

0

Like

Publications Which contain the keyword: HCV


2018-09-12 02:27:34 Keywords HCV, HBV, Co-infection,
Clinical, Laboratory, and Virological Profiles of Patients with Hepatitis C and B Co-infection in Upper Egypt
HCV/HBV co-infection most frequently occurs in specific high-risk populations. The present study was aimed to determine the Clinical, laboratory and virological characteristics of patients with hepatitis C and B co-infection. This study included 72 patients with positive both hepatitis B surface antigen (HBs Ag) and HCV Abs. Clinical data, laboratory and imaging data were collected. Quantitative HBV-DNA polymerase chain reaction ... Read more

2018-09-07 19:35:46 Keywords HCV,
Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker for diagnosis of HCV infection
_INTRODUCTION_ Hepatitis C is one of the most common liver diseases around the world. It is caused by hepatitis C virus (HCV) and a significant number of patients progress towards chronic hepatitis, hepatocellular carcinoma (HCC) and liver cirrhosis (HOOFNAGLE ET AL.,2002). Viral infection is the major cause of liver cirrhosis in about 20% of patients that after 10 years lead ... Read more

Psychiatric disturbances associated with Interferon therapy for HCV in Sohag Governorate.
:ABSTRACT Background: Psychiatric disturbances in chronic HCV infected patients under treatment by Pegylated-interferon and ribavirin combined therapy (PEG-IFN/Rib) still show worldwide controversy and no sufficient studies address this problem in Upper Egypt. Aim of the study: to detect the pattern and prevalence of psychiatric disturbances in chronic HCV infected (CHC) patients under PEG-IFN/Rib and the risk factors for these disturbances. ... Read more

2018-09-11 02:17:41 Keywords HCV, End-stage kidney disease, DAAs,
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease
BACKGROUND Till now, pooled data about the safety and efficacy of different direct-acting antiviral(DAAs) regimens in different renal situations are still under evaluation. AIM To evaluate a real-life experience of the efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) in patients with end-stage kidney disease (ESKD). PATIENTS AND METHODS Between January 2017 and January 2018, an open-label multicenter ... Read more